ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma (Nasdaq: AVBP) has appointed Brent S. Rice as Chief Commercial Officer (CCO). Rice brings over 25 years of experience in the biotechnology and pharmaceutical industry, most recently serving as SVP and global CCO at Autolus Therapeutics.
This strategic hire comes as ArriVent prepares for the potential approval and commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC). Rice's experience includes successfully transitioning Autolus from clinical-stage to commercial operations, leading Managed Markets at Juno Therapeutics, and spending 18 years at Amgen in various leadership roles.
ArriVent BioPharma (Nasdaq: AVBP) ha nominato Brent S. Rice come Chief Commercial Officer (CCO). Rice porta oltre 25 anni di esperienza nell’industria biotecnologica e farmaceutica, avendo recentemente ricoperto il ruolo di SVP e CCO globale presso Autolus Therapeutics.
Questa assunzione strategica arriva mentre ArriVent si prepara alla potenziale approvazione e commercializzazione di firmonertinib per NSCLC mutante EGFR. L’esperienza di Rice include la transizione di Autolus dalla fase clinica alle operazioni commerciali, la gestione dei mercati presso Juno Therapeutics e 18 anni presso Amgen in ruoli di leadership.
ArriVent BioPharma (Nasdaq: AVBP) ha designado a Brent S. Rice como Director Comercial (CCO). Rice aporta más de 25 años de experiencia en la industria biotecnológica y farmacéutica, habiendo ocupado recientemente el puesto de SVP y CCO global en Autolus Therapeutics.
Esta contratación estratégica llega mientras ArriVent se prepara para la posible aprobación y comercialización de firmonertinib para el cáncer de pulmón de células no pequeñas mutante EGFR. La experiencia de Rice incluye trasladar con éxito a Autolus de la etapa clínica a las operaciones comerciales, liderar Managed Markets en Juno Therapeutics y pasar 18 años en Amgen en diversos puestos de liderazgo.
ArriVent BioPharma (나스닥: AVBP)가 Brent S. Rice를 최고 상업 책임자(CCO)로 임명했습니다. Rice는 생명공학 및 제약 산업에서 25년 이상의 경력을 보유하고 있으며, 최근 Autolus Therapeutics에서 SVP 및 글로벌 CCO로 재직했습니다.
이 전략적 채용은 ArriVent가 EGFR 변이 NSCLC를 위한 firmonertinib의 승인 및 상용화 가능성에 대비하는 가운데 이루어집니다. Rice의 경력에는 Autolus를 임상 단계에서 상업 운영으로 성공적으로 전환한 경험, Juno Therapeutics에서 Managed Markets를 이끈 경험, 그리고 Amgen에서 18년간 다양한 리더십 역할을 수행한 경력이 포함됩니다.
ArriVent BioPharma (Nasdaq: AVBP) a nommé Brent S. Rice au poste de Chief Commercial Officer (CCO). Rice apporte plus de 25 ans d’expérience dans l’industrie biotechnologique et pharmaceutique, ayant récemment occupé les fonctions de SVP et CCO mondial chez Autolus Therapeutics.
Cette embauche stratégique intervient alors qu’ArriVent se prépare à l’éventuelle approbation et commercialisation du firmonertinib pour le cancer du poumon non à petites cellules muté EGFR. L’expérience de Rice comprend la transition réussie d’Autolus de la phase clinique aux opérations commerciales, la direction des Managed Markets chez Juno Therapeutics et 18 ans passés chez Amgen à des postes de direction.
ArriVent BioPharma (Nasdaq: AVBP) hat Brent S. Rice als Chief Commercial Officer (CCO) ernannt. Rice bringt über 25 Jahre Erfahrung in der Biotechnologie- und Pharmaindustrie mit und war zuletzt als SVP und globaler CCO bei Autolus Therapeutics tätig.
Diese strategische Personalie erfolgt, während ArriVent sich auf die potenzielle Zulassung und Vermarktung von Firmonertinib bei EGFR-mutiertem NSCLC vorbereitet. Rays Erfahrungen umfassen die erfolgreiche Transformation von Autolus von der klinischen Phase zu kommerziellen Operationen, die Leitung von Managed Markets bei Juno Therapeutics und 18 Jahre bei Amgen in verschiedenen Führungspositionen.
ArriVent BioPharma (ناسداك: AVBP) عيّنت برينت س. رايس كـ Chief Commercial Officer (CCO). يجلب رايس أكثر من 25 عاماً من الخبرة في صناعة biotech الصيدلانية، وكان آخر منصب له VP أول ورئيس تجاري عالمي في Autolus Therapeutics.
تأتي هذه التعيينات الاستراتيجية بينما تتحضر أري فنت لإحتمال الموافقة والتسويق لـ firmonertinib لسرطان الرئة غير صغير الخلايا ذو EGFRMut. تشمل خبرة رايس تحويل Autolus بنجاح من مرحلةClinical إلى عمليات تجارية، وقيادته لـ Managed Markets في Juno Therapeutics، وقضاء 18 عاماً في Amgen في مناصب قيادية.
ArriVent BioPharma（纳斯达克：AVBP） 已任命 Brent S. Rice 为首席商业官（CCO）。Rice 拥有超过 25 年的生物技术和制药行业经验，最近担任 Autolus Therapeutics 的 SVP 与全球 CCO。
此次战略性任命是在 ArriVent 为 EGFR 突变的非小细胞肺癌（NSCLC）适应证的 firmonertinib 的潜在批准与商业化做准备之际。Rice 的经验包括将 Autolus 从临床阶段成功过渡到商业运营，在 Juno Therapeutics 领导 Managed Markets，以及在 Amgen 积累的 18 年多次领导职位的经验。
- Strategic hire with 25+ years of commercial experience in biotech and pharma
- Proven track record in launching novel therapies and building commercial organizations
- Timing aligns with potential commercialization of firmonertinib for NSCLC
- Executive brings expertise in marketing, operations, and reimbursement strategy
- None.
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry.
“Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We are excited to welcome him to the ArriVent team at this pivotal stage of our growth. We believe his executive leadership experience will position us for success as firmonertinib nears potential approval and commercialization for EGFR mutant non-small cell lung cancer (NSCLC), and as we begin to unlock the potential of our ADC portfolio.”
Before joining ArriVent, Brent most recently served as the Senior Vice President and global Chief Commercial Officer, and Managing Director U.S. at Autolus Therapeutics Ltd. where he led global commercialization, commercial strategy and business portfolio management of their early and late-stage pipeline of next generation therapies. Under Brent's leadership, the company transitioned from a clinical stage development company to a commercial organization where he built the U.S. organization and led the successful introduction and launch of Autolus' first commercial product.
Mr. Rice added, “ArriVent has built a robust and science-driven pipeline that targets challenging and underserved areas in oncology. I look forward to partnering with the team to build a strong commercial foundation that drives growth and ensures patients access.”
An experienced executive leader, Brent brings cross-functional expertise in marketing, operations, and reimbursement, and building scalable commercial organizations, leading product launches, and negotiating high-value agreements that improve patient access. Prior to Autolus, Brent led Managed Markets at Juno Therapeutics, where he developed payer and reimbursement strategy capabilities. He spent 18 years at Amgen in roles of increasing responsibility, earning recognition as a strong cross-functional leader driving innovative partnerships and portfolio success.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, anticipated clinical milestones, the timing of, and results of, top-line pivotal Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, the approval of firmonertinib for commercialization by health authorities, the timing and results of commercialization of firmonertinib and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 3, 2025 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
Who is the new Chief Commercial Officer of ArriVent BioPharma (AVBP)?
What is Brent Rice's most recent experience before joining ArriVent (AVBP)?
What is the significance of this appointment for ArriVent (AVBP)?
What is Brent Rice's previous work experience in the pharmaceutical industry?
